Search & Analyze

Morepen Laboratories Ltd.

HealthcarePharmaceuticals & Drugs

www.morepen.com BSE: 500288NSE: MOREPENLAB

₹114.60BSE8.52%

16 Sep, 4:01 PM

₹114.60

₹6.28K Cr

44.69

4.82

7.96%

₹115.95

₹97.00

₹122.45

₹33.44

Customise metrics bar

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,853.50	36.77	4,44,716.74	0.86	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,199.70	83.50	2,44,223.13	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,823.05	84.11	1,83,453.32	0.79	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,105.00	24.42	1,10,224.17	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,359.75	32.59	1,09,848.55	0.96	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,906.00	94.19	1,02,983.51	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,145.25	29.67	95,591.76	0.70	435.60	-69.10%	8,099.80	-5.51%	13.75
Morepen Laboratories Ltd. MOREPENLAB	114.60	44.69	6,279.55	0.17	56.35	393.96%	570.13	34.07%	10.19

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Sep 2021	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	395.31	423.07	455.22	437.73	452.78	465.85	425.24	411.58	484.16	484.72	570.13
Expenses	353.29	374.69	403.60	393.66	416.64	423.61	401.07	380.88	437.84	460.27	487.59
	42.03	48.38	51.62	44.07	36.14	42.24	24.17	30.70	46.32	24.45	82.53
	10.63%	11.44%	11.34%	10.07%	7.98%	9.07%	5.68%	7.46%	9.57%	5.04%	14.48%
	11.97	4.24	3.43	4.99	5.34	4.61	4.41	30.46	3.81	8.46	5.18
Interest	0.00	0.80	1.15	1.18	1.34	4.67	4.04	4.18	4.32	3.88	4.84
	7.14	9.62	5.73	1.86	4.93	16.47	9.03	11.28	10.38	5.75	8.35
	46.86	41.74	48.17	46.02	35.21	25.72	15.52	45.53	35.44	23.33	74.53
	20.26%	32.25%	24.91%	24.28%	24.19%	21.01%	26.49%	10.22%	22.37%	32.52%	24.40%
	37.36	28.28	36.17	34.85	26.69	20.32	10.75	40.88	27.51	15.75	56.40
	0.83	0.55	0.71	0.64	0.49	0.37	0.20	0.75	0.50	0.29	1.03

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	1,546.83	1,417.53	1,690.43	1,811.58	1,805.69
	1,546.83	1,417.53	1,690.43	1,811.58	1,805.69
EXPENDITURE :
Increase/Decrease in Stock	-10.04	16.48	2.11	-47.12	-2.15
Raw Material Consumed	990.39	883.74	1,014.76	1,160.23	1,068.61
Power & Fuel Cost	18.93	23.78	34.09	40.62	44.90
Employee Cost	164.25	154.68	181.47	208.91	232.74
Other Manufacturing Expenses	98.99	91.70	95.75	102.62	125.33
General and Administration Expenses	42.38	55.44	66.63	67.17	73.16
Selling and Distribution Expenses	53.58	93.01	109.98	79.99	98.98
Miscellaneous Expenses	51.67	19.17	27.02	25.09	38.50
	1,410.15	1,338.00	1,531.81	1,637.51	1,680.06
Operating Profit (Excl OI)	136.67	79.53	158.62	174.07	125.63
	20.10	6.13	13.97	18.36	21.31
	156.77	85.67	172.60	192.43	146.94
Interest	2.43	1.98	3.71	8.34	16.41
PBDT	154.35	83.69	168.89	184.09	130.53
	27.64	27.93	33.47	28.98	36.43
Profit Before Taxation & Exceptional Items	126.70	55.76	135.42	155.11	94.09
Exceptional Income / Expenses					25.83
	126.70	55.76	135.42	155.11	119.92
Provision for Tax	25.02	17.08	38.80	37.09	24.27
	101.68	38.68	96.62	118.02	95.65
Extra items				0.00	0.00
Minority Interest	0.00	-0.00	-0.46	0.01	-0.77
Consolidated Net Profit	101.68	38.68	96.16	118.02	94.88
Profit Balance B/F	54.65	151.34	190.01	286.17	404.19
Appropriations	156.34	190.01	286.17	404.19	499.07
Equity Dividend %				10.00%	10.00%
	2.13	0.76	1.88	2.15	1.73
Adjusted EPS	2.13	0.76	1.88	2.15	1.73

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	95.56	102.23	102.23	109.58	109.58
Share Warrants & Outstandings	26.25
Total Reserves	456.75	650.68	745.00	1,046.65	1,136.85
Reserve excluding Revaluation Reserve	456.75	650.68	745.00	1,046.65	1,136.85
	578.56	752.91	847.23	1,156.23	1,246.44
Minority Interest	-0.46	-0.46		30.73	0.65
Secured Loans	1.32	0.93	3.36	5.76	4.49
Unsecured Loans				20.00	129.11
Deferred Tax Assets / Liabilities	2.48	2.69	2.25	6.98	16.46
Other Long Term Liabilities	3.45	3.52	4.50	17.91	7.43
Long Term Provisions	28.24	29.74	33.82	39.85	41.24
Total Non-Current Liabilities	35.50	36.88	43.93	90.49	198.73
Trade Payables	258.12	226.88	295.03	363.30	317.24
Other Current Liabilities	169.97	54.86	58.51	71.72	106.47
Short Term Borrowings	16.13	23.18	23.49	46.04	36.95
Short Term Provisions	12.24	16.24	25.02	19.60	29.64
Total Current Liabilities	456.46	321.16	402.04	500.65	490.30
Total Liabilities	1,070.05	1,110.50	1,293.21	1,778.10	1,936.12
Gross Block	613.25	656.24	620.63	828.38	796.70
Less: Accumulated Depreciation	361.45	389.27	313.28	339.87	283.70
Net Block	251.80	266.97	307.35	488.51	513.00
Capital Work in Progress	14.15	17.01	24.45	28.34	21.55
Non Current Investments			1.30	7.17	101.29
Long Term Investment			1.30	7.17	101.29
Long Term Loans & Advances	69.53	70.07	70.82	94.48	136.39
Other Non Current Assets	0.28	0.28	0.24	0.23	0.27
Total Non-Current Assets	335.75	354.33	404.16	618.73	772.51
Currents Investments				77.81	22.87
Inventories	275.85	228.89	248.59	299.97	271.83
Sundry Debtors	250.64	263.25	324.94	324.76	333.14
Cash and Bank	45.97	56.31	52.12	49.36	68.83
Other Current Assets	5.29	7.15	16.44	71.51	106.52
Short Term Loans and Advances	156.54	200.58	246.96	335.97	360.43
Total Current Assets	734.30	756.16	889.04	1,159.37	1,163.61
Net Current Assets (Including Current Investments)	277.84	435.00	487.00	658.72	673.31
Total Assets	1,070.05	1,110.50	1,293.21	1,778.10	1,936.12
Contingent Liabilities	2.64	6.66	9.76	18.32	335.40
Total Debt	18.57	25.16	29.00	79.39	194.69
	11.56	14.73	16.58	21.10	22.75
Adjusted Book Value	11.56	14.73	16.58	21.10	22.75

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	126.70	55.76	135.42	155.11	119.92
Adjustment	19.46	27.90	34.20	37.79	33.46
Changes In working Capital	-181.47	-158.28	-58.12	-123.69	-95.46
Cash Flow after changes in Working Capital	-35.31	-74.62	111.49	69.21	57.92
Cash Flow from Operating Activities	-60.24	-91.17	73.37	32.06	32.64
Cash Flow from Investing Activities	-31.68	-46.51	-83.30	-321.51	-123.42
Cash Flow from Financing Activitie	66.33	143.54	5.20	299.89	97.40
Net Cash Inflow / Outflow	-25.58	5.86	-4.72	10.44	6.62
Opening Cash & Cash Equivalents	41.39	15.80	21.67	16.95	27.38
Cash & Cash Equivalent on Amalgamation / Take over / Merger					-2.82
Closing Cash & Cash Equivalent	15.80	21.67	16.95	27.38	31.19

Ratios

Valuation

44.69

4.82

31.08

3.22

2.56

23.78

Profitability

7.96

10.19

5.15

6.96

5.30

Leverage & Liquidity

0.16

2.37

8.31

Returns

0.17

0.97

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	38.22	35.65	35.65	35.65	35.65	35.65	35.65	35.65	35.65
	3.82	3.79	3.87	3.62	3.24	3.13	2.88	2.84	2.75
	57.96	60.56	60.47	60.72	61.11	61.21	61.46	61.50	61.59
	61.78	64.35	64.35	64.35	64.35	64.35	64.35	64.35	64.35
No. of Shareholders	3,48,766	4,30,929	4,48,361	4,68,860	4,61,180	4,61,853	4,53,137	4,47,286	4,34,912

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-09-02	AGM
2026-07-28	Board Meeting	Quarterly Results
2026-05-26	Ex Dividend	Rs.0.2000 per share(10%)Final Dividend	2026-09-18	2026-09-19

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Morepen Laboratories Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

7 members across the board and senior leadership

Vipul Kumar Srivastava

Company Secretary & Compliance Officer

—

Sushil Suri

Chairman & Managing Director

₹2.75 Cr

Mar '26

Sanjay Suri

Managing Director

₹1.73 Cr

Mar '26

Praveen Kumar Dutt

Non Executive Independent Director

₹6.30 L

Mar '26

Ranjit Khattar

Non Executive Independent Director

₹5.90 L

Mar '26

Sharad Jain

Non Executive Independent Director

₹5.50 L

Mar '26

Savita

Non Executive Independent Director

₹4.70 L

Mar '26

MOREPENLAB Latest News

News

8 of 8 articles

EQUITY7 Sept 2026 · 11:20

Morepen Lab zooms on expanding reactor capacity for API, CDMO

The company has completed the first phase of its manufacturing capacity expansion program

COMPANY7 Sept 2026 · 11:14

Morepen Lab expands reactor capacity for API, CDMO

The company has completed the first phase of its manufacturing capacity expansion program

EQUITY7 Sept 2026 · 10:14

Morepen Laboratories informs about business update

EQUITY1 Jul 2026 · 14:29

Morepen Laboratories informs about press releases

EQUITY27 May 2026 · 15:07

Morepen Laboratories informs about newspaper publication

EQUITY27 May 2026 · 09:56

Morepen Laboratories informs about press release

EQUITY27 May 2026 · 09:55

Morepen Laboratories informs about investor presentation

EQUITY26 May 2026 · 17:47

Morepen Laboratories reports Profit after tax of Rs 201.23 Mln, in the March 2026 quarter

MOREPENLAB

₹114.60

+8.52%